Baseline characteristics of participants
| Characteristic . | Level . | Overall N = 50 . | Pediatric N = 26 . | Adult N = 24 . |
|---|---|---|---|---|
| Age (y), median (range) | 20.8 (1.2-71.9) | 11 (1.2-21.6) | 61.7 (22.5-71.9) | |
| Sex, n (%) | Female | 14 (28) | 8 (31) | 6 (25) |
| Male | 36 (72) | 18 (69) | 18 (75) | |
| Race, n (%) | Non-White | 23 (46) | 14 (54) | 9 (38) |
| White | 27 (54) | 12 (46) | 15 (63) | |
| Disease, n (%) | ALL | 8 (16) | 7 (27) | 1 (4) |
| AML | 19 (38) | 12 (46) | 7 (29) | |
| CML | 3 (6) | 3 (12) | 0 (0) | |
| MDS | 16 (32) | 3 (12) | 13 (54) | |
| Other | 4 (8) | 1 (4) | 3 (13) | |
| CIBMTR disease stage, n (%) | Advanced | 13 (27) | 2 (8) | 11 (48) |
| Early | 29 (60) | 19 (73) | 10 (43) | |
| Intermediate | 7 (14) | 5 (19) | 2 (9) | |
| Conditioning regimen, n (%) | Busulfan/cyclophosphamide | 7 (14) | 7 (27) | 0 (0) |
| Busulfan/fludarabine | 11 (22) | 9 (35) | 2 (8) | |
| Fludarabine/melphalan | 22 (44) | 2 (8) | 20 (83) | |
| Other | 3 (6) | 1 (4) | 2 (8) | |
| Total body irradiation/cyclophosphamide | 7 (14) | 7 (27) | 0 (0) | |
| Conditioning intensity, n (%) | Myeloablative | 27 (54) | 24 (92) | 3 (13) |
| Reduced intensity | 23 (46) | 2 (8) | 21 (88) | |
| Graft type, n (%) | BM | 28 (56) | 24 (92) | 4 (17) |
| Peripheral blood | 22 (44) | 2 (8) | 20 (83) |
| Characteristic . | Level . | Overall N = 50 . | Pediatric N = 26 . | Adult N = 24 . |
|---|---|---|---|---|
| Age (y), median (range) | 20.8 (1.2-71.9) | 11 (1.2-21.6) | 61.7 (22.5-71.9) | |
| Sex, n (%) | Female | 14 (28) | 8 (31) | 6 (25) |
| Male | 36 (72) | 18 (69) | 18 (75) | |
| Race, n (%) | Non-White | 23 (46) | 14 (54) | 9 (38) |
| White | 27 (54) | 12 (46) | 15 (63) | |
| Disease, n (%) | ALL | 8 (16) | 7 (27) | 1 (4) |
| AML | 19 (38) | 12 (46) | 7 (29) | |
| CML | 3 (6) | 3 (12) | 0 (0) | |
| MDS | 16 (32) | 3 (12) | 13 (54) | |
| Other | 4 (8) | 1 (4) | 3 (13) | |
| CIBMTR disease stage, n (%) | Advanced | 13 (27) | 2 (8) | 11 (48) |
| Early | 29 (60) | 19 (73) | 10 (43) | |
| Intermediate | 7 (14) | 5 (19) | 2 (9) | |
| Conditioning regimen, n (%) | Busulfan/cyclophosphamide | 7 (14) | 7 (27) | 0 (0) |
| Busulfan/fludarabine | 11 (22) | 9 (35) | 2 (8) | |
| Fludarabine/melphalan | 22 (44) | 2 (8) | 20 (83) | |
| Other | 3 (6) | 1 (4) | 2 (8) | |
| Total body irradiation/cyclophosphamide | 7 (14) | 7 (27) | 0 (0) | |
| Conditioning intensity, n (%) | Myeloablative | 27 (54) | 24 (92) | 3 (13) |
| Reduced intensity | 23 (46) | 2 (8) | 21 (88) | |
| Graft type, n (%) | BM | 28 (56) | 24 (92) | 4 (17) |
| Peripheral blood | 22 (44) | 2 (8) | 20 (83) |
ALL, acute lymphatic leukemia; AML, acute myelogenous leukemia; CIBMTR, Center for International Blood and Marrow Transplantation Research; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome.